Rockville, Maryland (US), July 11, 2022 – ABL, a pure play Contract Development and Manufacturing Organization (CDMO) specialized in the development and manufacturing of virus for vaccine candidates, gene and cancer therapies, today announces its partnership with KaliVir Immunotherapeutics, a privately held biotech company developing cutting-edge, next-generation oncolytic viral immunotherapy programs. ABL will manufacture KaliVir’s oncolytic viruses for its upcoming clinical trial. Read more
